MedTrace Logo

Next DPI LABA, Multicentre, 5-way Cross-over, Adult Asthmatic Patients

NCT00868023 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-03-30

No results posted yet for this study

Summary

Multinational, multicentre, randomised, double blind, double dummy, placebo and active controlled, 5-way cross over

Conditions

Interventions

DRUG

CHF 1535 Next DPI

CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)

DRUG

Foster BDP/Formoterol

BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)

DRUG

CHF 1535 Next DPI

CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)

DRUG

Foster BDP/Formoterol

BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    lead INDUSTRY

Principal Investigators

  • David Singh, Professor · Medecines Evaluation Unit - Southmoor Road - M23 9QZ Manchester - UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-07-31
Completion
2009-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00868023 on ClinicalTrials.gov